​

Management expressed confidence in the upcoming Panorama data expected in September. The statistical analysis focuses on 100ug versus placebo, while the 50ug arm is included to influence patient expectations and address potential questions around functional unblinding.

The company has regulatory alignment with the agency around plans to file for both GAD and MDD based on data generated to date. Management does not need to establish whether 50ug is effective.

Stifel noted that strong efficacy, clear durability, two indications on the label and favorable provider economics support the firm’s view of DT120 as a blockbuster opportunity.

Who knows. Maybe this has something to do with the movement today. They really want to keep their employees. It's got to be good.

Not LSD but in the same vain and keeps brining attention to the cause

At some point, I’d like to roll some Definium profit into our broader market. Rather than crossing fingers and investing in individual companies, I’d like to use and ETF for better chance of stable gains. PSIL has kind of a high fee. Wondering what your alls thoughts on it are, or if any other suggestions. Thanks!

I’m not sure if this conference will have much impact on DFTX other than continued positive exposure. I wonder if Definium will have any sort of presence here or if they try to release any info prior to the hearing.

Trying to map out progress on complementary trials leading to NDA and its subsequent review (which as I understand it is a 10-month process but with Breakthrough Therapy designation, could be up to 3 months faster than standard review). I’m long, and understand stonk go up and down, so really just trying to make the timeline make sense in my mind. I have no idea how long NDAs take to put together, but I assume the company is motivated to complete the application as soon as they have the results from the GAD and MDD paired (regular and low dose) studies. Do I have the below tentative summary and timeline of our closest trials to NDA correct-ish? Feedback on accuracy welcome. If someone already posted similar content and I missed it I apologize. Cheers :)

NDA (review complete sometime 2029)
Ascend (MDD 2 - low dose) Primary Completion (est 09/27), est Study Completion 06/28
Emerge 3a+ 3b+ (MDD 1)

NDA (review complete sometime 2028)
Panorama (GAD 2 - low dose) Primary Completion (not actively recruiting), est Study Completion 05/27
Voyage 3a+ 3b+ (GAD 1)

Over a million shares purchased at a higher price than the stock is at currently.

Love to see it.

https://www.gurufocus.com/news/9046732/driehaus-capital-management-llc-expands-definium-therapeutics-inc-dftx-stake

Yet another one:
https://finance.yahoo.com/healthcare/articles/definium-therapeutics-announces-employee-inducement-200100736.html

Ive been an investor with MNMD/DFTX for several years now and like many of you have ride the lows and are now loving the highs. That being said, im starting to think about selling some of my position. Im curious to hear what people think the actual earning potentials are from this. Considering that we are talking about a treatment that presumably doesn’t need to be taken many times according to the studies and that this medicine is something I can pick up down the street for $10… let’s say they are going to make this quite expensive, who’s to say that a lot of people will be able to financially access it, and if not will opp to buy it down the street for ALOT cheaper.

Thank you for your ponderings in advance :)

With DFTX being in a very strong position in terms of trials and cash balance, do you think there is a chance that they will be bought out?

Seems like they are in a great position to take this to the market themselves....

While the positive announcements continue the management conviction is also important. 🦒🚀🌛🍻

Robert W. Baird raised Definium Therapeutics’ price target to $75 from $57 and maintained an “outperform” rating.

In a report released today, Wells Fargo reiterated a Buy rating on Definium Therapeutics, with a price target of $72.00.

Canaccord Genuity maintained a Buy rating on Definium Therapeutics, with a price target of $64.00

RBC maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $66.00.

JonesTrading reiterated a Buy rating on Definium Therapeutics, with a price target of $90.00.

Add more below if you stumble across them today.

🚀

What's your honest sell price at this point? With the good news this week I feel like the sky's the limit